Nils Gleim

Nils Gleim

Auto-generated profile, based on publicly available information

Nils Gleim

Department of Radiation Oncology, University of Leipzig Medical Center, Germany; Comprehensive Cancer Center Central Germany, Partner Site Leipzig, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
NGN. Gleim
N. Gleim
ATA. Turcas
A. Turcas
GMG. Minniti
G. Minniti
AGAnca-Ligia Grosu
Anca-Ligia Grosu
TKTomas Kazda
Tomas Kazda
CSClemens Seidel
Clemens Seidel
Preservation of neurocognitive function is gaining importance for patients with brain metastases (BM). Several methods of neuroprotection in radiotherapy of BM have been developed and tested in prospective clinical trials, including stereotactic radiotherapy (SRT), hippocampal-sparing whole-brain radiotherapy (HS-WBRT) and concomitant memantine. The present analysis aimed to assess the current treatment patterns in European countries. We distributed an online survey among radiation oncologists (ROs) registered within the European Society for Radiotherapy and Oncology (ESTRO). Questions included characteristics of treatment centers and institutional standard operating procedures, focusing on the use of neuroprotective measures. The survey was completed by 234 ROs from 31 countries. WBRT is the preferred treatment modality over SRT for 4-5 BM for 18 % and for 6-10 BM for 53 % of ROs. While HS-WBRT is generally offered by most ROs (85 %), only a minority apply the technique regularly (25 %), and prescription parameters vary considerably. Concomitant memantine is prescribed by 30 % of ROs. Besides concerns about available evidence, limited staff capacity and reimbursement issues constitute frequent obstacles. Boost treatments as part of WBRT are rarely performed on a regular basis (22 %). Prognostic scores are used by a majority of ROs, while cognitive tests are not. There were significant differences between higher- and lower-income countries, and between university hospitals and other centers. There is considerable heterogeneity regarding neuroprotective radiotherapy approaches in European countries and regular application is limited. Besides clinical trial results, improved technical availability and reimbursement might be required to improve their utilization for BM treatment.

1 June 2021 in Computational and Systems Oncology
Verified
Journal Article
Open access
SHSaskia Haupt
Saskia Haupt
NGNils Gleim
Nils Gleim
AAAysel Ahadova
Aysel Ahadova
HBHendrik Bläker
Hendrik Bläker
MDMagnus von Knebel Doeberitz
Magnus von Knebel Doeberitz
VHVincent Heuveline
Vincent Heuveline
Lynch syndrome (LS), the most common inherited colorectal cancer (CRC) syndrome, increases the cancer risk in affected individuals. LS is caused by pathogenic germline variants in one of the DNA mismatch repair (MMR) genes, complete inactivation of which causes numerous mutations in affected cells. As CRC is believed to originate in colonic crypts, understanding the intra‐crypt dynamics caused by mutational processes is essential for a complete picture of LS CRC and may have significant implications for cancer prevention.We propose a computational model describing the evolution of colonic crypts during LS carcinogenesis. Extending existing modeling approaches for the non‐Lynch scenario, we incorporated MMR deficiency and implemented recent experimental data demonstrating that somaticCTNNB1mutations are common drivers of LS‐associated CRCs, if affecting both alleles of the gene. Further, we simulated the effect of different mutations on the entire crypt, distinguishing non‐transforming and transforming mutations.As an example, we analyzed the spread of mutations in the genesAPCandCTNNB1, which are frequently mutated in LS tumors, as well as of MMR deficiency itself. We quantified each mutation's potential for monoclonal conversion and investigated the influence of the cell location and of stem cell dynamics on mutation spread.Thein silicoexperiments underline the importance of stem cell dynamics for the overall crypt evolution. Further, simulating different mutational processes is essential in LS since mutations without survival advantages (the MMR deficiency‐inducing second hit) play a key role. The effect of other mutations can be simulated with the proposed model. Our results provide first mathematical clues towards more effective surveillance protocols for LS carriers.

10 January 2025 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
MCM. Czogalla
M. Czogalla
JSJ. Stöhr
J. Stöhr
NGN. Gleim
N. Gleim
KPK. Papsdorf
K. Papsdorf
SKS. Klagges
S. Klagges
CSClemens Seidel
Clemens Seidel
Therapeutic options for patients with brain metastases (BM) increase. While these lead to considerable survival effects in subgroups, there is limited knowledge about characteristics, prognosticators and treatment effects in patients with BM and short survival. Patients with a survival time of ≤ 6 months (short-term survivors, STS), diagnosed with BM between 2009-2021 at a large tertiary cancer center were analysed. Clinical and treatment characteristics, pathological data and causes of death were documented. Descriptive statistics, treatment-specific univariate Kaplan-Meier estimator analyses and multivariate Cox regression were performed. Among 1248 patients with BM, 480 (38 %) were STS. 256 STS with detailed clinical records were included in this analysis. In univariate and multivariate analysis, Karnofsky Performance Status (KPS) (p < 0.001) and number of BM (p = 0.004) were prognostic. In 75 % of patients, the ds-GPA score predicted short-term survival. Use of resection with focal radiotherapy (p < 0.001) and systemic treatment (p < 0.001) appeared prognostically favourable compared to whole brain radiotherapy (WBRT) alone. However, survival benefits were very modest, with a median gain of 6 weeks following resection and focal radiotherapy compared to whole-brain radiotherapy, and 3 weeks from systemic treatment. Systemic tumor progression was documented as the cause of death in the majority of patients. Over the examined time period, the ratio between STS and other patients remained without significant change. Within STS, KPS and number of BM are of prognostic relevance. There is benefit from local and systemic therapy to a limited extent. Shared and carefully discussed individual therapy decisions are necessary.

9 May 2026 in Radiotherapy and Oncology
Verified
Journal Article
Open access
ATAndrada Turcas
Andrada Turcas
AWAoife Williamson
Aoife Williamson
NGNils Gleim
Nils Gleim
TKTomas Kazda
Tomas Kazda
SFSharon Fernandez
Sharon Fernandez
Giuseppe MinnitiGiuseppe Minniti
Giuseppe Minniti
Radiotherapy (RT) represents a cornerstone treatment for brain and head-and-neck (H&N) tumours. Radiation-associated neurocognitive decline (ND) is a clinically relevant late effect. Dose-response relationships for ND and the contribution of specific brain substructures are incompletely characterized. This systematic review summarises current evidence on neurocognitive assessments, ND dose-volume predictors, and imaging correlates of radiation-induced injury. A systematic search of PubMed and Scopus/Embase identified studies reporting neurocognitive outcomes, dose-effect relationships, and imaging biomarkers in adults with brain and H&N tumours. Following PRISMA methodology, study selection was performed independently by three reviewers. Data on study design, RT characteristics, neurocognitive testing, and imaging findings were extracted and synthesised descriptively. Twenty-eight studies met the inclusion criteria. Most were small cohorts with heterogeneous neurocognitive testing. Verbal Learning Tests and Trail Making Test A/B were the most frequently used. ND was reported in 17 studies, with variable incidence (21%-79%). Memory was the most consistently affected domain and showed the strongest association with hippocampal dose. Higher doses to the temporal lobes, thalamus, amygdala, cerebellum, and corpus callosum were associated with deficits in executive function, processing speed, attention, and motor coordination. Advanced imaging demonstrated dose-dependent atrophy, white-matter disruption, perfusion changes, and metabolic alterations correlating with ND. ND after brain irradiation appears to be associated with dose-dependent injury involving multiple brain structures beyond the hippocampus. Current exploratory evidence requires validation in larger prospective studies with standardized neurocognitive assessment, imaging protocols, and long-term follow-up to refine dose constraints and improve neurocognitive preservation.

21 April 2024 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
NGN. Gleim
N. Gleim
ARAlexander Rühle
Alexander Rühle
SHS. Heider
S. Heider
FNF. Nägler
F. Nägler
FGFrank Anton Giordano
Frank Anton Giordano
CSClemens Seidel
Clemens Seidel
Many patients with solid tumors develop brain metastases (BM). With more patients surviving long-term, preservation of neurocognitive function gains importance. In recent years, several methods to delay cognitive deterioration have been tested in clinical trials. However, knowledge on the extent to which these neuroprotective strategies have been implemented in clinical practice is missing. We performed an online survey regarding treatment patterns of BM in German-speaking countries, focused on the use of neuroprotective approaches. The survey was distributed among radiation oncologists (ROs) registered within the database of the German Society for Radiation Oncology (DEGRO). Physicians of 78 centers participated in the survey. Whole brain radiotherapy (WBRT) is still preferred by 70 % of ROs over stereotactic radiotherapy (SRT) in patients with 6–10 BM. For 4–5 BM WBRT is preferred by 23 % of ROs. The fraction of ROs using hippocampal sparing (HS) in WBRT has increased to 89 %, although the technique is used on a regular basis only by a minority (26 %). The drug memantine is not widely prescribed (14% of ROs). A trend was observed for university hospitals to implement neuroprotective approaches more frequently. There is considerable heterogeneity regarding the treatment of BM in German-speaking countries and a general standard of care is lacking. Neuroprotective strategies are not yet standard approaches in daily clinical routine, although usage is increasing. Further clinical trials, as well as improvement of technical opportunities and reimbursement, might further shift the treatment landscape towards neuroprotective radiation treatments in the future.

23 November 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
ATAndrada Turcas
Andrada Turcas
RBRaphael Bodensohn
Raphael Bodensohn
ECElena Clerici
Elena Clerici
IDIsacco Desideri
Isacco Desideri
FEFelix Ehret
Felix Ehret
MNMaximilian Niyazi
Maximilian Niyazi
Reirradiation is increasingly considered for patients with recurrent primary brain tumours, yet clinical practices vary significantly due to limited evidence and a lack of standardized guidelines. This survey aimed to map European practice patterns in brain tumour reirradiation. A 23-item web-based survey was developed by the ESTRO CNS Focus Group to assess institutional characteristics, clinical decision-making, and technical aspects of reirradiation. Distributed via email and social media, the survey collected responses between June-July 2025. Descriptive statistics were applied. Eighty responses from 28 European countries were analysed. High-grade gliomas were the most frequently reirradiated tumours (>80 %), followed by meningioma (56 %, low-grade glioma (49 %), and ependymoma (44 %). Conventional photon radiotherapy (RT) was the predominant technique across all tumour types, with varying use of hypofractionation, stereotactic RT, and proton therapy. Target volume definition and margin size varied by histology, with larger margins and inclusion of edema/cavities more frequent in gliomas. MRI-CT fusion was standard for planning. Concurrent systemic treatment was used mainly in high-grade gliomas. Organ at risk dose recovery and cumulative constraints were commonly considered, but threshold values and recovery models differed. Main barriers included fear of toxicities, including radiation necrosis and limited evidence. This survey reveals high heterogeneity in brain tumour reirradiation practices across Europe, especially regarding dose, technique, and target definition. Despite shared principles, consensus is lacking for rarer tumour types. These findings underscore the need for harmonized guidelines and prospective data to optimize patient care.